News
Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 ...
AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...
AstraZeneca has signed a research agreement worth more than $5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the ...
AstraZeneca (AZ) and CSPC Pharmaceuticals Group have entered into a partnership worth up to $5.3bn to develop therapies for ...
CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...
The announcement builds on AZ's announcement earlier this year that it will invest $2.5 billion in an R&D facility in China, ...
Hot Stocks}SANDS CHINA LTD quoted at HK$15.66, up 5.2% 17/06/2025 10:18 {Hot Stocks}SINO BIOPHARM quoted at HK$5.13, down 2.8% 17/06/2025 10:11 {Hot Stocks}CSPC PHARMA(01093) quoted at HK$8.49, down 3 ...
AstraZeneca is paying CSPC Pharmaceutical Group $110 million up front to tap that China-based biotech’s artificial intelligence-driven technology for discovering and developing novel oral drugs.
The drug licensing talks cover the development, production and sale of a targeted cancer therapy and other CSPC Pharma ...
AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.
Davey D and Lina Girl discuss the hottest trends in technology from gaming to life-saving devices to apps that make you ...
AstraZeneca will pay CSPC upfront fee of $110 million Additional potential payments of up to $5.22 billion to CSPC Deal latest of AstraZeneca efforts to bolster China business, AI The deal marks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results